$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

$egrx Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000082787114000013 Filed on August 11, 2014

Income Statement

Concept	2014 Q2	2013 Q2
Revenue	$5.792M	$5.075M
YoY Change	14.13%
Cost Of Revenue	$1.556M	$2.925M
YoY Change	-46.8%
Gross Profit	$4.236M	$2.150M
YoY Change	97.02%
Gross Profit Margin	73.14%	42.36%
Selling, General & Admin	$2.673M	$1.251M
YoY Change	113.66%
% of Gross Profit	63.1%	58.19%
Research & Development	$4.545M	$1.632M
YoY Change	178.44%
% of Gross Profit	107.29%	75.92%
Depreciation & Amortization	$20.00K	$60.00K
YoY Change	-66.67%	-68.42%
% of Gross Profit	0.47%	2.79%
Operating Expenses	$8.774M	$3.815M
YoY Change	129.97%
Operating Profit	-$2.982M	$1.260M
YoY Change	-336.71%
Interest Expense	$5.000K	$16.02K
YoY Change	-68.79%
% of Operating Profit		1.27%
Other Income/Expense, Net	$48.00K	-$505.2K
YoY Change	-109.5%
Pretax Income	-$2.934M	$754.6K
YoY Change	-488.83%
Income Tax	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$2.934M	$754.6K
YoY Change	-488.83%
Net Earnings / Revenue	-50.66%	14.87%
Basic Earnings Per Share	-$0.21
Diluted Earnings Per Share	-$0.21	$245.9K
COMMON SHARES
Basic Shares Outstanding	14.02M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$49.80M	$10.80M
YoY Change	361.11%
Cash & Equivalents	$49.79M	$10.80M
Short-Term Investments		$0.00
Other Short-Term Assets	$408.8K	$3.900M
YoY Change	-89.52%
Inventory	$329.0K	$300.0K
Prepaid Expenses
Receivables	$6.712M	$300.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$57.76M	$15.30M
YoY Change	277.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$359.5K	$400.0K
YoY Change	-10.12%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$45.00K	$0.00
YoY Change
Total Long-Term Assets	$404.5K	$500.0K
YoY Change	-19.1%
TOTAL ASSETS
Total Short-Term Assets	$57.76M	$15.30M
Total Long-Term Assets	$404.5K	$500.0K
Total Assets	$58.16M	$15.80M
YoY Change	268.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.521M	$1.600M
YoY Change	57.53%
Accrued Expenses	$7.469M	$1.500M
YoY Change	397.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$16.25M	$13.50M
YoY Change	20.36%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$0.00	$700.0K
YoY Change	-100.0%
Total Long-Term Liabilities	$0.00	$700.0K
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$16.25M	$13.50M
Total Long-Term Liabilities	$0.00	$700.0K
Total Liabilities	$16.20M	$14.20M
YoY Change	14.08%
SHAREHOLDERS EQUITY
Retained Earnings	-$95.07M
YoY Change
Common Stock	$14.02K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.91M	$1.600M
YoY Change
Total Liabilities & Shareholders Equity	$58.16M	$15.80M
YoY Change	268.1%

Cashflow Statement

Concept	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$2.934M	$754.6K
YoY Change	-488.83%
Depreciation, Depletion And Amortization	$20.00K	$60.00K
YoY Change	-66.67%	-68.42%
Cash From Operating Activities	-$4.660M	-$3.750M
YoY Change	24.27%	-62.08%
INVESTING ACTIVITIES
Capital Expenditures	-$10.00K	-$30.00K
YoY Change	-66.67%	0.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$10.00K	-$30.00K
YoY Change	-66.67%	-100.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-420.0K	9.830M
YoY Change	-104.27%	-24675.0%
NET CHANGE
Cash From Operating Activities	-4.660M	-3.750M
Cash From Investing Activities	-10.00K	-30.00K
Cash From Financing Activities	-420.0K	9.830M
Net Change In Cash	-5.090M	6.050M
YoY Change	-184.13%	-210.81%
FREE CASH FLOW
Cash From Operating Activities	-$4.660M	-$3.750M
Capital Expenditures	-$10.00K	-$30.00K
Free Cash Flow	-$4.650M	-$3.720M
YoY Change	25.0%	-62.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	9828737	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	0	USD
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2520523	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1192600	USD
CY2014Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6712244	USD
CY2013Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5124182	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3129552	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7468794	USD
CY2014Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	419242	USD
CY2013Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	274566	USD
CY2013Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	169568	USD
CY2014Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	244158	USD
CY2013Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	14203995	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136970460	USD
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	0	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	381736	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2073694	USD
CY2013Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	128313	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	163500	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	329919	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	381736	USD
CY2014Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2013Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	436350	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1090878	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2014Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	96417	USD
CY2013Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	38567	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4506639	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8485931	shares
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	990330	shares
CY2013Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8340837	shares
CY2013Q3	us-gaap	Assets Assets	18102620	USD
CY2014Q2	us-gaap	Assets Assets	58159637	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	17482407	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	57755128	USD
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. It is recommended that these condensed financial statements be read in conjunction with the financial statements and related notes that appear in Eagle Pharmaceuticals, Inc.'s (the "Company") final prospectus filed by the Company with the SEC on </font><font style="font-family:inherit;font-size:10pt;">February 13, 2014</font><font style="font-family:inherit;font-size:10pt;">, relating to the Company's Registration Statement on Form S-1 (File No. 001-36306) for the Company's initial public offering. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made. Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">June 30, 2014</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ending September 30,</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2014</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter.</font></div></div>
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10455565	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49790920	USD
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10801361	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5066886	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	39335355	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5734475	USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	974311	shares
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14020133	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3048131	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	14020133	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3048131	shares
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	14020	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	3048	USD
	us-gaap	Cost Of Revenue CostOfRevenue	9539436	USD
CY2014Q2	us-gaap	Cost Of Revenue CostOfRevenue	1555711	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4449337	USD
CY2013Q2	us-gaap	Cost Of Revenue CostOfRevenue	2925046	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	10062296	USD
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2013Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	171607	USD
CY2014Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	0	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6259653	USD
CY2013Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	10019653	USD
	us-gaap	Depreciation Depreciation	105327	USD
	us-gaap	Depreciation Depreciation	81762	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1666063	USD
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.06
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.23
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
CY2014Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2013Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	15608	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	15608	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	573582	USD
	us-gaap	Professional Fees ProfessionalFees	0	USD
CY2013Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	754576	USD
CY2014Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2934079	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10168457	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7430505	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1294905	USD
CY2013Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2014Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-898703	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	194775	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1327923	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1588062	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1263875	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	4489848	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	185681	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3760000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	892341	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	199666	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	329034	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1320	USD
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-30000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	16018	USD
	us-gaap	Interest Expense InterestExpense	6244	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	4812	USD
	us-gaap	Interest Expense InterestExpense	309121	USD
CY2014Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	0	USD
	us-gaap	Interest Expense Debt InterestExpenseDebt	545000	USD
CY2013Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	218000	USD
	us-gaap	Interest Paid InterestPaid	6244	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	0	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	329034	USD
CY2014Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	329034	USD
CY2013Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	USD
CY2014Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	329034	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	26647	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2156	USD
CY2013Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1036	USD
CY2014Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	17826	USD
CY2014Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	68104	USD
CY2013Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	63873	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	208457	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	270482	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18102620	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	58159637	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14341805	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16248970	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	117977	USD
CY2014Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	596024	USD
CY2013Q2	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	0	USD
	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	685937	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46088917	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9828737	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38815	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1469325	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5563587	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6714747	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8873552	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-2934079	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	754576	USD
	us-gaap	Net Income Loss NetIncomeLoss	-6531802	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10539615	USD
CY2013Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-320061	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9236369	USD
CY2014Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2934079	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	48319	USD
CY2013Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-505175	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1506666	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-517589	USD
	us-gaap	Operating Expenses OperatingExpenses	25939075	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	8774274	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	3815278	USD
	us-gaap	Operating Expenses OperatingExpenses	14962768	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2982398	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	1259751	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9650868	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5923839	USD
CY2014Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	249714	USD
CY2014Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	824786	USD
CY2013Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	69182	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	408789	USD
CY2013Q3	us-gaap	Other Assets Current OtherAssetsCurrent	31856	USD
CY2013Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	46320	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	45000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	332	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35590	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35305	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3202	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	3765000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2014Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	3500000	USD
CY2013Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1179	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38815	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	30675	USD
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1500000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	922930	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1902660	USD
CY2014Q2	us-gaap	Prepaid Insurance PrepaidInsurance	514141	USD
	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	1500000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20868	USD
CY2013Q3	us-gaap	Prepaid Insurance PrepaidInsurance	117510	USD
	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	6500000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46069228	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46069228	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20868	USD
CY2014Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	20868	USD
CY2014Q2	us-gaap	Professional Fees ProfessionalFees	0	USD
	us-gaap	Professional Fees ProfessionalFees	-1993099	USD
CY2013Q2	us-gaap	Professional Fees ProfessionalFees	-1993099	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	359509	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	402286	USD
CY2014Q2	us-gaap	Purchase Obligation PurchaseObligation	751000	USD
CY2013Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1632280	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4545158	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6375896	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10927912	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95073813	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102136057	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	8774407	USD
CY2014Q2	us-gaap	Royalty Revenue RoyaltyRevenue	1941526	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	5349289	USD
CY2013Q2	us-gaap	Royalty Revenue RoyaltyRevenue	2585719	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	350350	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3689640	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	3748800	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2489310	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	9038929	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	16288207	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	5791876	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	5075029	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2673405	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1251051	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6130634	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5471727	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	381736	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	329920	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.64
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.64
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5684
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.3965
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.3658
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0323
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0247
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0216
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0216
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0211
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0095
CY2013Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0082
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0177
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3450000	shares
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46048360	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	41910667	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	-87929014	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1666063	USD
	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	2704567	USD
CY2013Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	1074637	USD
CY2014Q2	us-gaap	Temporary Equity Dividends Adjustment TemporaryEquityDividendsAdjustment	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of condensed financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the condensed financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed financial statements, actual results may materially vary from these estimates.</font></div></div>
CY2013Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1706829	USD
CY2014Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	0	USD
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3048131	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	8590719	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	3020889	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14020133	shares
CY2013Q3	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	62737	USD
CY2014Q2	egrx	Accrued Product Costs Current AccruedProductCostsCurrent	4000	USD
CY2013Q3	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	282682	USD
CY2014Q2	egrx	Accrued Researchand Development Current AccruedResearchandDevelopmentCurrent	815057	USD
	egrx	Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense	309121	USD
	egrx	Adjustments Noncash Itemsto Reconcile Net Income Lossto Cash Providedby Usedin Operating Activities Noncash Interest Expense AdjustmentsNoncashItemstoReconcileNetIncomeLosstoCashProvidedbyUsedinOperatingActivitiesNoncashInterestExpense	0	USD
CY2012Q1	egrx	Asset Purchase Agreement Royalty On Net Profitsof Products Term AssetPurchaseAgreementRoyaltyOnNetProfitsofProductsTerm	P10Y
	egrx	Classof Warrantor Right Expected Term ClassofWarrantorRightExpectedTerm	P6Y
CY2008Q2	egrx	Collaborative Product Development Agreement Cumulative Milestones Upon Achievementof Goals CollaborativeProductDevelopmentAgreementCumulativeMilestonesUponAchievementofGoals	13000000	USD
CY2008Q2	egrx	Collaborative Product Development Agreement Monthly Receivable CollaborativeProductDevelopmentAgreementMonthlyReceivable	200000	USD
CY2008Q2	egrx	Collaborative Product Development Agreement Non Refundable Amount Receivedfor Signing CollaborativeProductDevelopmentAgreementNonRefundableAmountReceivedforSigning	750000	USD
CY2008Q2	egrx	Collaborative Product Development Agreement Paymentfor Product Development CollaborativeProductDevelopmentAgreementPaymentforProductDevelopment	2000000	USD
	egrx	Deferred Ipo Costs DeferredIPOCosts	0	USD
	egrx	Deferred Ipo Costs DeferredIPOCosts	2704567	USD
CY2014Q2	egrx	Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment	6000000	USD
CY2013Q3	egrx	Deferred Revenue Divestitureof Business Refund Dueto Insufficient Milestone Attainment DeferredRevenueDivestitureofBusinessRefundDuetoInsufficientMilestoneAttainment	6000000	USD
CY2012Q1	egrx	Expected Cash Proceeds Upon Regulatory Approval Milestone ExpectedCashProceedsUponRegulatoryApprovalMilestone	1000000	USD
CY2014Q2	egrx	Expected Cash Proceedson Additional Milestones Dependenton Licensor Sales Activity ExpectedCashProceedsonAdditionalMilestonesDependentonLicensorSalesActivity	3000000	USD
	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	9295	USD
	egrx	Income Taxes Paid Franchise Taxes Paid IncomeTaxesPaidFranchiseTaxesPaid	2335	USD
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	3346062	USD
	egrx	Increase Decreasein Prepaid Expenseand Other Current Assets Total IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal	-979730	USD
	egrx	Lawsuit Invoked Regulatory Stayof Approval LawsuitInvokedRegulatoryStayofApproval	P30M
	egrx	Marketing Rights Term MarketingRightsTerm	P10Y
CY2012Q1	egrx	Milestonereductionfor Regulatory Approvalof Generic Competitor Minimum MilestonereductionforRegulatoryApprovalofGenericCompetitorMinimum	500000	USD
	egrx	Orphan Drug Exclusivity Regulatory Agency Stayof Application Incremental Domestic Periodfor Pediatric Exclusivity OrphanDrugExclusivityRegulatoryAgencyStayofApplicationIncrementalDomesticPeriodforPediatricExclusivity	P6M
	egrx	Orphan Drug Exclusivity Regulatory Agency Stayof Application Maximum Period OrphanDrugExclusivityRegulatoryAgencyStayofApplicationMaximumPeriod	P7Y
CY2013Q3	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	1023291	USD
CY2014Q2	egrx	Prepaid Fda User Fee PrepaidFDAUserFee	0	USD
CY2013Q3	egrx	Prepaid Product Costs PrepaidProductCosts	730003	USD
CY2014Q2	egrx	Prepaid Product Costs PrepaidProductCosts	0	USD
	egrx	Product Development Agreements Exclusive Rights Acquired Numberof Products ProductDevelopmentAgreementsExclusiveRightsAcquiredNumberofProducts	33	product
	egrx	Royalty Revenue Commercial Partners Obligationof Sales Report Term RoyaltyRevenueCommercialPartnersObligationofSalesReportTerm	P60D
CY2014Q1	egrx	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1788	shares
CY2014Q1	egrx	Stock Issued During Period Shares Warrants Exercised StockIssuedDuringPeriodSharesWarrantsExercised	1788	shares
	egrx	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	20868	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000827871
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14020133	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Eagle Pharmaceuticals, Inc.

Files In Submission

Name	View Source	Status
0000827871-14-000013-index-headers.html	Edgar Link	pending
0000827871-14-000013-index.html	Edgar Link	pending
0000827871-14-000013.txt	Edgar Link	pending
0000827871-14-000013-xbrl.zip	Edgar Link	pending
egrx-20140630.xml	Edgar Link	completed
egrx-20140630.xsd	Edgar Link	pending
egrx-20140630_cal.xml	Edgar Link	unprocessable
egrx-20140630_def.xml	Edgar Link	unprocessable
egrx-20140630_lab.xml	Edgar Link	unprocessable
egrx-20140630_pre.xml	Edgar Link	unprocessable
egrx_q3x2014.htm	Edgar Link	pending
exhibit311q3.htm	Edgar Link	pending
exhibit312q3.htm	Edgar Link	pending
exhibit321q3.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx

2014 Q2 Form 10-Q Financial Statement

#000082787114000013 Filed on August 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX EAGLE PHARMACEUTICALS, INC. Stock $egrx

2014 Q2 Form 10-Q Financial Statement

#000082787114000013 Filed on August 11, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EGRX
EAGLE PHARMACEUTICALS, INC. Stock $egrx